Yoon Suk Jung1, Minkyung Han2, Sohee Park3, Won Ho Kim4, Jae Hee Cheon4. 1. Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Department of Public Health, Graduate School, Yonsei University, Seoul, Republic of Korea. 3. Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Republic of Korea. 4. Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
Abstract
BACKGROUND AND AIMS: The association between inflammatory bowel disease [IBD] and cancer remains poorly defined in Asian populations. Therefore, we conducted a nationwide population-based study to determine the cancer risk in Korean patients with IBD. METHODS: Using the National Health Insurance claims data, we collected data on patients diagnosed with IBD (5595 Crohn's disease [CD] and 10 049 ulcerative colitis [UC]) from 2011 to 2014. Standardized incidence ratios [SIRs] of overall and site-specific cancers in IBD patients in comparison with the general population were calculated. RESULTS: The overall cancer risk was higher in CD patients [SIR, 2.2; 95% confidence interval, 1.5-3.0 in men and 3.3; 2.4-4.5 in women] and UC patients [1.9; 1.6-2.3 in men and 1.9; 1.5-2.4 in women]. There were significantly increased risks for the following cancers: small bowel cancer [31.2; 3.8-112.8], colorectal cancer [CRC] [3.7; 1.6-7.2] and haematological cancer [4.0; 1.1-10.3] in men with CD; small bowel cancer [61.1; 7.4-220.6], CRC [4.7; 1.5-10.9], liver cancer [15.3; 5.6-33.2], pancreatic cancer [8.6; 1.0-31.0] and haematological cancer [11.0; 3.6-25.7] in women with CD; CRC [2.1; 1.3-3.3] and cancer of the prostate [3.5; 2.1-5.5], brain/central nervous system [6.1; 1.3-17.9] and thyroid [2.2; 1.1-3.9] in men with UC; and CRC [3.0; 1.5-5.3], cancer of the liver [4.4; 1.6-9.7] and cervix uteri [5.7; 2.4-11.1], and haematological cancer [3.5; 1.1-8.1] in women with UC. Women with CD had an increased risk of non-Hodgkin lymphoma [NHL] and leukaemia. Women with UC had an increased risk of NHL. CONCLUSIONS: Korean patients with IBD are at increased risk for overall, intestinal and haematological cancer.
BACKGROUND AND AIMS: The association between inflammatory bowel disease [IBD] and cancer remains poorly defined in Asian populations. Therefore, we conducted a nationwide population-based study to determine the cancer risk in Korean patients with IBD. METHODS: Using the National Health Insurance claims data, we collected data on patients diagnosed with IBD (5595 Crohn's disease [CD] and 10 049 ulcerative colitis [UC]) from 2011 to 2014. Standardized incidence ratios [SIRs] of overall and site-specific cancers in IBD patients in comparison with the general population were calculated. RESULTS: The overall cancer risk was higher in CD patients [SIR, 2.2; 95% confidence interval, 1.5-3.0 in men and 3.3; 2.4-4.5 in women] and UC patients [1.9; 1.6-2.3 in men and 1.9; 1.5-2.4 in women]. There were significantly increased risks for the following cancers: small bowel cancer [31.2; 3.8-112.8], colorectal cancer [CRC] [3.7; 1.6-7.2] and haematological cancer [4.0; 1.1-10.3] in men with CD; small bowel cancer [61.1; 7.4-220.6], CRC [4.7; 1.5-10.9], liver cancer [15.3; 5.6-33.2], pancreatic cancer [8.6; 1.0-31.0] and haematological cancer [11.0; 3.6-25.7] in women with CD; CRC [2.1; 1.3-3.3] and cancer of the prostate [3.5; 2.1-5.5], brain/central nervous system [6.1; 1.3-17.9] and thyroid [2.2; 1.1-3.9] in men with UC; and CRC [3.0; 1.5-5.3], cancer of the liver [4.4; 1.6-9.7] and cervix uteri [5.7; 2.4-11.1], and haematological cancer [3.5; 1.1-8.1] in women with UC. Women with CD had an increased risk of non-Hodgkin lymphoma [NHL] and leukaemia. Women with UC had an increased risk of NHL. CONCLUSIONS: Korean patients with IBD are at increased risk for overall, intestinal and haematological cancer.
Authors: Jacob A Burns; Adam B Weiner; William J Catalona; Eric V Li; Edward M Schaeffer; Stephen B Hanauer; Scott Strong; James Burns; Maha H A Hussain; Shilajit D Kundu Journal: Eur Urol Date: 2018-12-04 Impact factor: 20.096
Authors: Travis J Meyers; Adam B Weiner; Rebecca E Graff; Anuj S Desai; Lauren Folgosa Cooley; William J Catalona; Stephen B Hanauer; Jennifer D Wu; Edward M Schaeffer; Sarki A Abdulkadir; Shilajit D Kundu; John S Witte Journal: Int J Cancer Date: 2020-05-29 Impact factor: 7.396
Authors: Marilia L Montenegro; Juan E Corral; Frank J Lukens; Baoan Ji; Paul T Kröner; Francis A Farraye; Yan Bi Journal: Dig Dis Sci Date: 2021-02-24 Impact factor: 3.199
Authors: Su Young Kim; Yeon Seo Cho; Hyun-Soo Kim; Jung Kuk Lee; Hee Man Kim; Hong Jun Park; Hyunil Kim; Jihoon Kim; Dae Ryong Kang Journal: Gut Liver Date: 2021-11-18 Impact factor: 4.321
Authors: Franziska Moll; Maria Walter; Flávia Rezende; Valeska Helfinger; Estefania Vasconez; Tiago De Oliveira; Florian R Greten; Catherine Olesch; Andreas Weigert; Heinfried H Radeke; Katrin Schröder Journal: Front Immunol Date: 2018-05-08 Impact factor: 7.561